Optimizing management of myelodysplastic syndromes post-allogeneic transplantation

References

• Ho AY, Pagliuca A, Kenyon M et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood104(6), 1616–1623 (2004).
   PubMed Web of Science ®Google Scholar
• Martino R, Iacobelli S, Brand R et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using hla-identical sibling donors in myelodysplastic syndromes. Blood108(3), 836–846 (2006).
   PubMed Web of Science ®Google Scholar
• Scott BL, Sandmaier BM, Storer B et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia20(1), 128–135 (2006).
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Shem-Tov N et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia20(2), 322–328 (2006).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J. Clin. Oncol.29(5), 516–523 (2011).
   PubMed Web of Science ®Google Scholar
• Alyea EP, Kim HT, Ho V et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood105(4), 1810–1814 (2005).
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia12(Suppl. 1), S25–S29 (1998).
   PubMedGoogle Scholar
• Deeg HJ, Shulman HM, Anderson JE et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood95(4), 1188–1194 (2000).
   PubMedGoogle Scholar
• Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J. Clin. Oncol.25(23), 3503–3510 (2007).
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Della Porta MG, Bacigalupo A et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood112(3), 895–902 (2008).
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Lim SN et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transplant.45(3), 450–457 (2010).
   PubMed Web of Science ®Google Scholar
• McClune BL, Weisdorf DJ, Pedersen TL et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J. Clin. Oncol.28(11), 1878–1887 (2010).
   PubMed Web of Science ®Google Scholar
• Nevill TJ, Fung HC, Shepherd JD et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood92(6), 1910–1917 (1998).
   PubMed Web of Science ®Google Scholar
• Nevill TJ, Shepherd JD, Sutherland HJ et al. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Biol. Blood Marrow Transplant.15(2), 205–213 (2009).
   PubMed Web of Science ®Google Scholar
• Schanz J, Steidl C, Fonatsch C et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J. Clin. Oncol.29(15), 1963–1970 (2011).
   PubMed Web of Science ®Google Scholar
• Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood112(7), 2681–2686 (2008).
   PubMed Web of Science ®Google Scholar
• Laport GG, Sandmaier BM, Storer BE et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol. Blood Marrow Transplant.14(2), 246–255 (2008).
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Artz AS, Stock W et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant.40(11), 1027–1032 (2007).
   PubMed Web of Science ®Google Scholar
• Porter DL, Antin JH. Donor leukocyte infusions in myeloid malignancies: new strategies. Best Pract. Res. Clin. Haematol.19(4), 737–755 (2006).
   PubMedGoogle Scholar
• Schmid C, Labopin M, Nagler A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J. Clin. Oncol.25(31), 4938–4945 (2007).
   PubMed Web of Science ®Google Scholar
• Oran B, Giralt S, Couriel D et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia21(12), 2540–2544 (2007).
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Binder M, Schmid C, Rutt C, Ehninger G, Bornhauser M. Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation. Haematologica93(8), 1276–1278 (2008).
   PubMed Web of Science ®Google Scholar
• Czibere A, Bruns I, Kroger N et al. 5-azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant.45(5), 872–876 (2009).
   PubMedGoogle Scholar
• Guièze R JA, Itzykson R , Thepot S, Guillaume T, Coiteux V, Wittnebel S. Azacytidine (AZA) in relapsed MDS and AML after allogeneic stem cell transplantation (allo-HSCT): results of the french ATU program. Presented at: 52nd ASH meeting. Orlando, FL, USA, 4–7 December 2010.
   Google Scholar
• Goodyear O, Agathanggelou A, Novitzky-Basso I et al. Induction of a CD8+ T-cell response to the mage cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood116(11), 1908–1918 (2010).
   PubMed Web of Science ®Google Scholar
• Lubbert M, Bertz H, Wasch R et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant.45(4), 627–632 (2010).
   PubMed Web of Science ®Google Scholar
• Schroeder TCA, Kröger N, Platzbecker U, Bug G, Rieger K, Luft T. Azacitidine (Vidaza®, AZA) and donor lymphocyte infusions (DLI) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) relapsing after allogeneic hematopoietic stem cell transplantation (HSCT): interim-analysis from the azarelatrial. Presented at: 52nd ASH meeting. Orlando, FL, USA, 4–7 December 2010.
   Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol.10(3), 223–232 (2009).
   PubMed Web of Science ®Google Scholar
• de Lima M, Giralt S, Thall PF et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer116(23), 5420–5431 (2010).
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl J. Med.355(14), 1456–1465 (2006).
   PubMed Web of Science ®Google Scholar
• List A, Kurtin S, Roe DJ et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl J. Med.352(6), 549–557 (2005).
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Jadersten M, Forsblom AM et al. Lenalidomide inhibits the malignant clone and up-regulates the sparc gene mapping to the commonly deleted region in 5q- syndrome patients. Proc. Natl Acad. Sci. USA104(27), 11406–11411 (2007).
   PubMed Web of Science ®Google Scholar
• Wei S, Chen X, Rocha K et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc. Natl Acad. Sci. USA106(31), 12974–12979 (2009).
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson SP et al. Orally administered lenalidomide (cc-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and AKT phosphorylation in vitro. Microvasc. Res.69(1–2), 56–63 (2005).
   PubMed Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood108(2), 618–621 (2006).
   PubMed Web of Science ®Google Scholar
• Kneppers E, van der Holt B, Kersten MJ et al. Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood118(9), 2413–2419 (2011).
   PubMed Web of Science ®Google Scholar
• Thiede C. Diagnostic chimerism analysis after allogeneic stem cell transplantation: new methods and markers. Am. J. Pharmacogenomics4(3), 177–187 (2004).
   PubMedGoogle Scholar
• Mattsson J, Uzunel M, Tammik L, Aschan J, Ringden O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia15(12), 1976–1985 (2001).
   PubMedGoogle Scholar
• Thiede C, Bornhauser M, Oelschlagel U et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia15(2), 293–302 (2001).
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Oelschlaegel U, Platzbecker U et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica94(11), 1613–1617 (2009).
   PubMed Web of Science ®Google Scholar
• Jung SW, Lee SY, Jekarl DW et al. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution. Leuk Res.35(6), 735–740 (2010).
   PubMedGoogle Scholar
• Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood112(4), 965–974 (2008).
   PubMed Web of Science ®Google Scholar
• Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood103(6), 2316–2324 (2004).
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med.360(22), 2289–2301 (2009).
   PubMed Web of Science ®Google Scholar
• Langemeijer SM, Kuiper RP, Berends M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet.41(7), 838–842 (2009).
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia25(7), 1147–1152 (2011).
   PubMed Web of Science ®Google Scholar
• Thol F, Friesen I, Damm F et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J. Clin. Oncol.29(18), 2499–2506 (2011).
   PubMed Web of Science ®Google Scholar
• Bains A, Luthra R, Medeiros LJ, Zuo Z. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am. J. Clin. Pathol.135(1), 62–69 (2011).
   PubMed Web of Science ®Google Scholar
• Wells DA, Benesch M, Loken MR et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the ipss and with outcome after hematopoietic stem cell transplantation. Blood102(1), 394–403 (2003).
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Flowers ME, Lee SJ et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood118(2), 456–463 (2011).
   PubMed Web of Science ®Google Scholar
• Bader P, Niemeyer C, Willasch A et al. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by preemptive immunotherapy. Br. J. Haematol.128(5), 649–658 (2005).
   PubMedGoogle Scholar
• Tobiasson M, Olsson R, Hellstrom-Lindberg E, Mattsson J. Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant.46(5), 719–726 (2011).
   PubMedGoogle Scholar
• Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control9(2), 123–137 (2002).
   PubMedGoogle Scholar
• Platzbecker UWM, Radke J, Kiani A, Seltmann F, Röllig C, von Bonin M. Minimal residual disease (MRD) based preemptive 5-azacytidine treatment can prevent or delay imminent relapse in patients with high-risk MDS or AML after allogenic HSCT – results of the “RELAZA” trial. Leukemia doi:10.1038/leu.2011.234 (2011) (Epub ahead of print).
   Google Scholar
• Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract. Res. Clin. Haematol.21(3), 437–453 (2008).
   PubMed Web of Science ®Google Scholar
• Akatsuka Y, Morishima Y, Kuzushima K, Kodera Y, Takahashi T. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions. Cancer Sci.98(8), 1139–1146 (2007).
   PubMedGoogle Scholar
• Warren EH, Fujii N, Akatsuka Y et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood115(19), 3869–3878 (2010).
   PubMed Web of Science ®Google Scholar
• Cutler C, Li S, Ho VT et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood109(7), 3108–3114 (2007).
   PubMed Web of Science ®Google Scholar
• Platzbecker U, von Bonin M, Goekkurt E et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol. Blood Marrow Transplant.15(1), 101–108 (2009).
   PubMed Web of Science ®Google Scholar
• Cutler C, Stevenson K, Kim HT et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood112(12), 4425–4431 (2008).
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Schuler U, Porksen G et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation67(4), 499–504 (1999).
   PubMedGoogle Scholar
• Nash RA, Johnston L, Parker P et al. A Phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant.11(7), 495–505 (2005).
   PubMed Web of Science ®Google Scholar
• Finke J, Bethge WA, Schmoor C et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre Phase 3 trial. Lancet Oncol.10(9), 855–864 (2009).
   PubMed Web of Science ®Google Scholar
• van Besien K, Artz A, Smith S et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol.23(24), 5728–5738 (2005).
   PubMed Web of Science ®Google Scholar
• Lim ZY, Ho AY, Ingram W et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br. J. Haematol.135(2), 201–209 (2006).
   PubMed Web of Science ®Google Scholar
• Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia21(7), 1387–1394 (2007).
   PubMed Web of Science ®Google Scholar
• Parmar S, Andersson BS, Couriel D et al. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a Phase I/II controlled, adaptively randomized study. J. Clin. Oncol.29(3), 294–302 (2011).
   PubMed Web of Science ®Google Scholar
• Sun K, Welniak LA, Panoskaltsis-Mortari A et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl Acad. Sci. USA101(21), 8120–8125 (2004).
   PubMed Web of Science ®Google Scholar
• Koreth J, Stevenson KE, Kim HT et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood114(18), 3956–3959 (2009).
   PubMed Web of Science ®Google Scholar
• Orciuolo E, Galimberti S, Petrini M. Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro. Leuk. Res.31(7), 1026–1027 (2007).
   PubMedGoogle Scholar
• Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol. Res.47(1–3), 65–77 (2010).
   PubMed Web of Science ®Google Scholar
• Tuve S, Gayoso J, Scheid C et al. Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia25(5), 880–883 (2011).
   PubMed Web of Science ®Google Scholar
• Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr. Opin. Hematol.17(6), 493–499 (2010).
   PubMed Web of Science ®Google Scholar
• Bondanza A, Valtolina V, Magnani Z et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood107(5), 1828–1836 (2006).
   PubMed Web of Science ®Google Scholar
• Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bordignon C, Bonini C. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum. Gene Ther.21(3), 241–250 (2010).
   PubMed Web of Science ®Google Scholar
• Bonini C, Grez M, Traversari C et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat. Med.9(4), 367–369 (2003).
   PubMed Web of Science ®Google Scholar
• Ciceri F, Bonini C, Gallo-Stampino C, Bordignon C. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy7(2), 144–149 (2005).
   PubMed Web of Science ®Google Scholar
• Nguyen VH, Shashidhar S, Chang DS et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood111(2), 945–953 (2008).
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Falzetti F, Carotti A et al.In situ prevent GvHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood117(14), 3921–3928 (2011).
   PubMed Web of Science ®Google Scholar
• Jarvis M, Marzolini M, Wang XN, Jackson G, Sviland L, Dickinson AM. Heat shock protein 70: correlation of expression with degree of graft-versus-host response and clinical graft-versus-host disease. Transplantation76(5), 849–853 (2003).
   PubMedGoogle Scholar
• Kaiser T, Kamal H, Rank A et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood104(2), 340–349 (2004).
   PubMed Web of Science ®Google Scholar
• Weissinger EM, Schiffer E, Hertenstein B et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood109(12), 5511–5519 (2007).
   PubMed Web of Science ®Google Scholar
• Dreyfus F. The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev.22(Suppl. 2), S29–S34 (2008).
   PubMed Web of Science ®Google Scholar
• Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev.23(Suppl. 1), S15–S19 (2009).
   PubMed Web of Science ®Google Scholar
• Takatoku M, Uchiyama T, Okamoto S et al. Retrospective nationwide survey of japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur. J. Haematol.78(6), 487–494 (2007).
   PubMed Web of Science ®Google Scholar
• Mahindra A, Bolwell B, Sobecks R et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br. J. Haematol.146(3), 310–316 (2009).
   PubMed Web of Science ®Google Scholar
• Kanamori HTT, Numata A, Tanaka M, Ishigatsubo Y, Maruta A. Prognostic impact of posttransplantation serum ferritin in allogeneic stem cell transplantation for leukemia or myelodysplastic syndrome. Presented at: 52nd ASH meeting. Orlando, FL, USA, 4–7 December 2010.
   Google Scholar
• Kamble RT, Selby GB, Mims M, Kharfan-Dabaja MA, Ozer H, George JN. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.12(5), 506–510 (2006).
   PubMed Web of Science ®Google Scholar
• Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T. Non-transferrin-bound iron during allogeneic stem cell transplantation. Br. J. Haematol.113(3), 836–838 (2001).
   PubMed Web of Science ®Google Scholar
• Kroger N, Bornhauser M, Ehninger G et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann. Hematol.82(6), 336–342 (2003).
   PubMed Web of Science ®Google Scholar
• Ruutu T, Volin L, Beelen DW et al. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective Phase II trial. Presented at: 52nd ASH meeting. Orlando, FL, USA, 4–7 December 2010.
   Google Scholar
• Lim Z, Brand R, Martino R et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J. Clin. Oncol.28(3), 405–411 (2010).
   PubMed Web of Science ®Google Scholar
• Kröger N, Shimoni A, Zabelina T et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (ALLOSCT) in elderly patients with secondary acute myeloid leukemia (SAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant.37(4), 339–344 (2006).
   PubMed Web of Science ®Google Scholar
• Campregher PV, Gooley T, Scott BL et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant.40(10), 965–971 (2007).
   PubMedGoogle Scholar
• Kurosawa S, Fukuda T, Tajima K et al. Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation. Am. J. Hematol.84(12), 815–820 (2009).
   PubMed Web of Science ®Google Scholar
• Oliva EN, Dimitrov BD, Benedetto F, D’Angelo A, Nobile F. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk. Res.29(10), 1217–1219 (2005).
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Chen E, Corral M et al. Incidence and clinical complications of myelodysplastic syndromes among united states medicare beneficiaries. J. Clin. Oncol.28(17), 2847–2852 (2010).
   PubMed Web of Science ®Google Scholar
• Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr. Med. Res. Opin.25(1), 139–147 (2009).
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Bornhauser M, Germing U et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol. Blood Marrow Transplant.14(11), 1217–1225 (2008).
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Della Porta MG, Bacigalupo A et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica95(3), 476–484 (2010).
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Rhodes J et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol. Blood Marrow Transplant.17(6), 852–860 (2010).
   PubMed Web of Science ®Google Scholar
• Busca A, Falda M, Manzini P et al. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol. Blood Marrow Transplant.16(1), 115–122 (2010).
   PubMed Web of Science ®Google Scholar
• Lim ZY, Fiaccadori V, Gandhi S et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk. Res.34(6), 723–727 (2010).
   PubMed Web of Science ®Google Scholar